The Study
Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals 2025, 18, 185”
This study is like a letter to the editor where scientists argue about what other scientists wrote. It's not a real experiment where they tested something on people or animals. It's just smart people giving their opinion about what other research is missing. Think of it like a book review - it tells you what's good or bad about other books, but it's not a new book itself.
Analysis score
Maximum 0 for a editorial/opinion.
Where the score came from
Scientists are arguing about whether a peptide called BPC 157 is safe and effective. One group says it helps with healing and has no side effects. Another group points out that almost all research comes from one lab, studies only use one tiny dose, and nobody has proven it actually works in humans.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1For a human considering BPC 157 supplements, this means there is no solid proof the peptide works or is safe.
- 2Most research comes from one lab, doses tested in animals don't match commercial products, and the one human study was cancelled.
- 3Over 80% of BPC 157 studies from one research group; only single doses tested in animals; plasma half-life under 30 minutes; no published tumor inhibition studies in living animals; only one clinical trial was cancelled
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Pharmaceuticals
Year
2025
Authors
Michalina Józwiak, Marta Bauer, Wojciech Kamysz, Patrycja Kleczkowska
Related Content
Claims (3)
There's only been one official clinical trial testing BPC 157 in humans, and it was cancelled. The other safety data we have comes from tiny, unpublished studies that aren't reliable enough to prove this peptide is safe or works as a medicine.
A peptide called BPC 157 helps grow new blood vessels in injured muscles and tendons, but scientists worry this same blood vessel growth could also help tumors grow - and they haven't done enough safety studies to check if it causes cancer.
Scientists haven't done proper human tests to see if certain peptide supplements like BPC-157, Ipamorelin, or CJC-1295 actually help with recovery, sleep, or body composition.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.